Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
PARP - Google News
Get the latest updates from PARP - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated about 2 years ago
Ovarian Cancer Patient Case: Prognosis and Molecular Testing - Targeted Oncology
about 2 years ago
Ovarian Cancer Patient Case: Prognosis and Molecular Testing Targeted Oncology
PARP Inhibition in Ovarian Cancer: Safety Profiles and Dose Adjustment - Targeted Oncology
about 2 years ago
PARP Inhibition in Ovarian Cancer: Safety Profiles and Dose Adjustment Targeted Oncology
Considering PARP Inhibitor Maintenance in Ovarian Cancer - Targeted Oncology
about 2 years ago
Considering PARP Inhibitor Maintenance in Ovarian Cancer Targeted Oncology
PARP Inhibitor Market Dynamics: A Podcast :: Scrip - Scrip
about 2 years ago
PARP Inhibitor Market Dynamics: A Podcast :: Scrip ScripPARP Inhibitor Biomarkers Market...
Merck looks for a return on its Lynparza investment - Vantage
about 2 years ago
Merck looks for a return on its Lynparza investment Vantage
Lynparza first PARP inhibitor to demonstrate overall survival benefit - The Pharma Letter
about 2 years ago
Lynparza first PARP inhibitor to demonstrate overall survival benefit The Pharma Letter
Part 2: Using PARP Inhibitors Beyond Recommended Duration in Ovarian Cancer - Targeted Oncology
about 2 years ago
Part 2: Using PARP Inhibitors Beyond Recommended Duration in Ovarian Cancer Targeted...
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial - StreetInsider.com
about 2 years ago
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline...
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer - AstraZeneca
about 2 years ago
Lynparza reduced risk of death by 32% in the adjuvant treatment of...
'Game-changing' drug cuts risk of women dying from breast cancer by a third - The Mirror
about 2 years ago
'Game-changing' drug cuts risk of women dying from breast cancer by a...
'Game-changing' drug cuts risk of women dying from breast cancer by a third - The Mirror
about 2 years ago
'Game-changing' drug cuts risk of women dying from breast cancer by a...
LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer - StreetInsider.com
about 2 years ago
LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment...